Gemcitabine in Treating Patients With Newly Diagnosed, Relapsed, or Chemotherapy-Resistant Mantle Cell Lymphoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00234026
Recruitment Status : Completed
First Posted : October 6, 2005
Last Update Posted : June 5, 2012
Information provided by (Responsible Party):
Swiss Group for Clinical Cancer Research